Reported Earnings • 3h
First quarter 2026 earnings released: NT$0.32 loss per share (vs NT$0.094 loss in 1Q 2025) First quarter 2026 results: NT$0.32 loss per share (further deteriorated from NT$0.094 loss in 1Q 2025). Net loss: NT$39.6m (loss widened 238% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 14
Full year 2025 earnings released: NT$0.92 loss per share (vs NT$0.68 loss in FY 2024) Full year 2025 results: NT$0.92 loss per share (further deteriorated from NT$0.68 loss in FY 2024). Net loss: NT$114.1m (loss widened 38% from FY 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Announcement • Mar 13
Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, Jun 11, 2026 Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, Jun 11, 2026. Location: 2 floor no,24, sec.1 hang chou s. rd., jhongjheng district, taipei city Taiwan Reported Earnings • Nov 18
Third quarter 2025 earnings released: NT$0.29 loss per share (vs NT$0.077 loss in 3Q 2024) Third quarter 2025 results: NT$0.29 loss per share (further deteriorated from NT$0.077 loss in 3Q 2024). Net loss: NT$35.0m (loss widened 258% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 31
Second quarter 2025 earnings released: NT$0.16 loss per share (vs NT$0.22 loss in 2Q 2024) Second quarter 2025 results: NT$0.16 loss per share (improved from NT$0.22 loss in 2Q 2024). Net loss: NT$19.8m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Announcement • Jun 20
Gongwin Pet Biopharm Co., Ltd Announces Special Export License for the Animal Drug “Anengkang Injection” Approved by APHIA Gongwin Biopharm Holdings Co., Ltd. announced that its subsidiary, Gongwin Pet Biopharm Co., Ltd. (hereinafter referred to as “Gongwin Pet”), has applied to the (APHIA)(MOA) for a special export license for the animal drug “Anengkang Injection” (Animal Drug Foreign No. 00027) and has been approved. Gongwin Pet obtained the license for the animal drug ”Anengkang Injection” and commissioned TAH-AN CHEMICAL & PHARMACEUTICAL CO., LTD.'s first plant to manufacture the drug. The period of authorized manufacturing approval is from June 16, 2025 to December 31, 2030. Reported Earnings • May 14
First quarter 2025 earnings released: NT$0.09 loss per share (vs NT$0.23 loss in 1Q 2024) First quarter 2025 results: NT$0.09 loss per share (improved from NT$0.23 loss in 1Q 2024). Net loss: NT$11.7m (loss narrowed 54% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Announcement • May 06
Gongwin Biopharm Holdings Co., Ltd. to Report Q1, 2025 Results on May 13, 2025 Gongwin Biopharm Holdings Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025 New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (NT$32m revenue, or US$986k). Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change). Reported Earnings • Mar 20
Full year 2024 earnings released: NT$0.68 loss per share (vs NT$0.89 loss in FY 2023) Full year 2024 results: NT$0.68 loss per share (improved from NT$0.89 loss in FY 2023). Net loss: NT$82.5m (loss narrowed 18% from FY 2023). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Announcement • Mar 14
Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, Jun 16, 2025 Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, Jun 16, 2025. Location: 2 floor no,24, sec.1 hang chou s. rd., jhongjheng district, taipei city Taiwan Announcement • Mar 05
Gongwin Biopharm Holdings Co., Ltd. to Report Q4, 2024 Results on Mar 13, 2025 Gongwin Biopharm Holdings Co., Ltd. announced that they will report Q4, 2024 results on Mar 13, 2025 Reported Earnings • Nov 19
Third quarter 2024 earnings released: NT$0.08 loss per share (vs NT$0.15 loss in 3Q 2023) Third quarter 2024 results: NT$0.08 loss per share (improved from NT$0.15 loss in 3Q 2023). Net loss: NT$9.79m (loss narrowed 42% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. New Risk • Sep 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (NT$32m revenue, or US$985k). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding). Announcement • Aug 15
Gongwin Biopharm Holdings Co., Ltd. to Report Q2, 2024 Results on Aug 22, 2024 Gongwin Biopharm Holdings Co., Ltd. announced that they will report Q2, 2024 results on Aug 22, 2024 New Risk • Jun 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (NT$24m revenue, or US$752k). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • May 19
First quarter 2024 earnings released: NT$0.22 loss per share (vs NT$0.19 loss in 1Q 2023) First quarter 2024 results: NT$0.22 loss per share (further deteriorated from NT$0.19 loss in 1Q 2023). Net loss: NT$25.5m (loss widened 21% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Announcement • Mar 14
Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, Jun 21, 2024 Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, Jun 21, 2024. Location: 2nd Floor, No.24, Sec. 1, Hangzhou S. Rd., Zhongzheng Dist., Taipei Taiwan Agenda: To consider 2023 Annual Business Report; to consider 2023 Audit Report of Final Accounts by Audit Committee; to consider Report on the implementation status of the Company's Sound Operation Plan; to consider Report on the Company's 2023 remuneration distributions for employees and directors; to consider Report on the reasons why the Shareholders proposals were not included in the motions. New Risk • Jul 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (NT$1.1m revenue, or US$36k). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Announcement • Mar 06
Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, May 17, 2022 Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, May 17, 2022. Reported Earnings • Apr 13
Full year 2020 earnings released: NT$0.89 loss per share (vs NT$1.07 loss in FY 2019) Full year 2020 results: Net loss: NT$93.1m (loss narrowed 15% from FY 2019). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 18
Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, Jun 01, 2021 Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, Jun 01, 2021. Is New 90 Day High Low • Feb 01
New 90-day low: NT$145 The company is down 26% from its price of NT$196 on 04 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Dec 05
New 90-day high: NT$262 The company is up 81% from its price of NT$145 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 19
New 90-day high: NT$250 The company is up 66% from its price of NT$151 on 21 August 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 04
New 90-day high: NT$196 The company is up 50% from its price of NT$131 on 06 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. Is New 90 Day High Low • Oct 19
New 90-day high: NT$171 The company is up 29% from its price of NT$133 on 21 July 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. 